{"product_id":"maravai-pestle-analysis","title":"Maravai PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic clarity with our targeted PESTLE Analysis of Maravai—spot regulatory, economic, and tech trends shaping its biotech trajectory and sharpen your investment or competitive strategy; purchase the full report for the complete, actionable breakdown and ready-to-use formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS-China Geopolitical Tensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe BIOSECURE Act and related 2024 measures have accelerated reshoring, reducing US biotech imports from China by an estimated 28% in 2024; Maravai, as a US-based nucleic acid supplier with 2024 revenue around $280M, is positioned to capture displaced demand. \u003c\/p\u003e\n\u003cp\u003eHowever, tightening export controls and CFIUS-style reviews add compliance costs and constrain international sales, potentially raising operating expenses by several percentage points. \u003c\/p\u003e\n\u003cp\u003eThese shifts favor regionalized manufacturing and secure sourcing for critical reagents, reinforcing Maravai’s strategic value to domestic pharma and government biodefense contracts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic investment in pandemic preparedness and genomic research drives Maravai’s Nucleic Acid Production; US federal pandemic preparedness funding rose to about $9.5B in FY2024, supporting suppliers of raw materials and reagents.\u003c\/p\u003e \n\u003cp\u003eShifts in NIH budget—$49.9B enacted for FY2024—and BARDA appropriations can materially affect contract volumes for Maravai’s custom oligos and mRNA reagents.\u003c\/p\u003e \n\u003cp\u003ePolitical reprioritization toward or away from mRNA therapeutics could alter near-term demand; monitoring Congressional and HHS funding proposals for 2025 is critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical moves toward harmonizing biologics and vaccine regulations—such as FDA-EMA convergence initiatives that cut duplicate reviews by an estimated 20%—help Maravai streamline global operations and reduce compliance spend for clients handling \u0026gt;$30bn in annual biologics R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eCollaborative frameworks between FDA and EMA lower compliance costs for Maravai’s multinational customers, enabling faster market entry—recent joint guidelines sped approvals by up to 3–6 months for some therapies.\u003c\/p\u003e\n\u003cp\u003eA rise in protectionist policies, however, could disrupt cross-border approvals, raising operational overheads and potentially increasing compliance costs by double-digit percentages for multinational supply chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical pressure from the US Inflation Reduction Act, which enables Medicare negotiation projected to lower drug revenues by up to 10–20% for affected drugs, pressures pharma clients to cut R\u0026amp;D budgets, potentially reducing demand for Maravai’s discovery services.\u003c\/p\u003e\n\u003cp\u003eIf biotech margins tighten, many firms may shift away from early-stage spending; Maravai must highlight technologies that can shorten timelines and cut development costs—e.g., platform efficiencies that reduce per-project costs by estimated 15–30%—to retain clients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIRA-driven price pressures: potential 10–20% revenue impact\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D budget cuts risk lowering early-stage outsourcing demand\u003c\/li\u003e\n\u003cli\u003eMaravai should promote cost-saving, time-reducing platforms (15–30% per-project savings)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Security and Bio-defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClassification of biotech as critical infrastructure has increased US government oversight and funding, including $3.2B in BioShield\/BARDA appropriations in 2024 that prioritize domestic supply chains; Maravai's nucleic acid reagents support onshoring and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003eMaravai supplies clinical-grade mRNA and oligonucleotide inputs used in rapid-response vaccine production, contributing to incumbent contractors' surge capacity during emergencies.\u003c\/p\u003e\n\u003cp\u003eOngoing political focus on biosecurity—reflected in multi-year federal procurement plans and grants—creates durable demand for high-quality reagents, supporting Maravai's revenue stability in 2024–25.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 BARDA\/BioShield funding ~$3.2B\u003c\/li\u003e\n\u003cli\u003eHigher domestic sourcing mandates boost demand for clinical-grade nucleic acids\u003c\/li\u003e\n\u003cli\u003eMaravai positioned as key supplier for rapid vaccine scale-up\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReshoring lifts Maravai demand as export controls and IRA squeeze drug revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical trends—US BIOSECURE reshoring (imports from China down ~28% in 2024), FY2024 NIH $49.9B, federal pandemic preparedness ~$9.5B and BARDA\/BioShield ~$3.2B—boost Maravai’s domestic demand but tighter export controls\/CFIUS and IRA-driven Medicare negotiation (potential drug revenue cuts 10–20%) raise compliance costs and pressure clients’ R\u0026amp;D budgets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS imports from China (biotech change)\u003c\/td\u003e\n\u003ctd\u003e-28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH budget\u003c\/td\u003e\n\u003ctd\u003e$49.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePandemic preparedness\u003c\/td\u003e\n\u003ctd\u003e$9.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA\/BioShield\u003c\/td\u003e\n\u003ctd\u003e$3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug revenue risk (IRA)\u003c\/td\u003e\n\u003ctd\u003e-10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Maravai across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—each backed by data and current trends to identify threats and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Maravai’s full PESTLE into a concise, shareable brief that’s easy to drop into presentations or strategy packs for quick team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Capital Markets Recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStabilization of US interest rates by late 2025 has revived biotech VC and IPO activity, with 2025 biotech IPO proceeds reaching about $8.2B and VC funding rising 28% year-over-year, boosting customer access to capital. Maravai customers are reallocating funds to outsourced mRNA\/nucleic acid manufacturing and safety testing, lifting industry CMO demand ~22% in 2025. This economic rebound supports sustaining Nucleic Acid Production growth beyond pandemic peaks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation raised specialty reagent and skilled-labor costs for bioprocessing: U.S. chemical prices were up about 6% year-over-year in 2024, while biotech wage growth averaged ~5–7%, forcing Maravai to boost operational efficiency across its sites.\u003c\/p\u003e\n\u003cp\u003eRising costs for laboratory supplies and reagents pressured margins even as Maravai held service pricing steady; in 2024 gross margin for CDMO\/biologics testing peers averaged ~38–42%, a benchmark Maravai must defend.\u003c\/p\u003e\n\u003cp\u003eEffective supply-chain strategies—longer-term supplier contracts and regional sourcing—and automated production lines are essential to offset 4–6% annual input-cost increases and protect EBITDA in a high-cost environment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D Expenditure Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpmacroeconomic shifts influencing global life sciences r spending reached an estimated us billion in correlate with maravai biosciences revenue given its exposure to reagents and biologics tools.\u003e\n\u003cplarge pharma maintained roughly flat r budgets in while smaller biotech funding fell making their spending more cyclical and sensitive to economic downturns.\u003e\n\u003cpmaravai diversified portfolio across genomics biologics and specialty reagents helped offset localized downturns in specific therapeutic areas supporting revenue resilience financials.\u003e\n\u003c\/pmaravai\u003e\u003c\/plarge\u003e\u003c\/pmacroeconomic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Maravai scales in Europe and Asia, FX exposure rises; a 10% USD appreciation versus the euro in 2024 would make European sales roughly 10% pricier locally, pressuring volumes. Maravai reported ~35% of 2024 revenue from outside the US, increasing sensitivity to USD\/EUR and USD\/JPY swings. The company uses forward contracts and currency options to hedge receivables, targeting stable cash flows and a hedging coverage ratio above 60%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~35% 2024 revenue international\u003c\/li\u003e\n\u003cli\u003e10% USD rise ≈ 10% price pressure in EUR markets\u003c\/li\u003e\n\u003cli\u003eHedging coverage target \u0026gt;60% (for receivables)\u003c\/li\u003e\n\u003cli\u003eInstruments: forwards and options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe biotech labor shortage drives wage inflation; median biotech scientist salaries rose ~7% in 2024 to ~$115,000, intensifying recruitment pressure for Maravai’s specialized nucleic acid teams.\u003c\/p\u003e\n\u003cp\u003eMaravai must allocate higher labor spend and targeted development—R\u0026amp;D headcount growth may cost 10–15% more annually—to retain expertise critical for complex synthesis.\u003c\/p\u003e\n\u003cp\u003eSlower hiring or higher churn can delay scaling and pipeline timelines; labor-market tightness risks extending time-to-volume by quarters and increasing unit costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 median biotech scientist salary ~$115,000 (+7%)\u003c\/li\u003e\n\u003cli\u003eEstimated R\u0026amp;D labor premium 10–15% higher\u003c\/li\u003e\n\u003cli\u003eHiring delays can push scale-up timelines by quarters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech rebound fuels CDMO demand but rising costs squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic tailwinds in 2024–25: biotech IPOs\/VC rebound (2025 IPO proceeds ~$8.2B; VC +28% YoY) lifted CMO demand ~22%; input inflation raised chemical prices ~6% (2024) and biotech wages ~7% (median $115k), pressuring margins (peer CDMO gross margin 38–42%); international sales ~35% of 2024 revenue with hedging \u0026gt;60% to mitigate FX.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech IPO proceeds\u003c\/td\u003e\n\u003ctd\u003e$8.2B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC funding change\u003c\/td\u003e\n\u003ctd\u003e+28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemical price inflation\u003c\/td\u003e\n\u003ctd\u003e~6% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian scientist pay\u003c\/td\u003e\n\u003ctd\u003e$115,000 (+7% 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational revenue\u003c\/td\u003e\n\u003ctd\u003e~35% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eMaravai PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Maravai PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning or investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751715582329,"sku":"maravai-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/maravai-pestle-analysis.png?v=1772234243","url":"https:\/\/matrixbcg.com\/products\/maravai-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}